All In MedTech

Device Trial Radar · NCT04519541

RAMBAM 021: Safety and Initial Feasibility of the Neurolyser XR for the Treatment of Chronic Low Back Pain

Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain

Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Feb 3, 2021

Primary completion

Sep 11, 2022

Study completion Jan 31, 2023

Sponsor

Lead sponsor
FUSMobile Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Rambam Health Care Campus
First posted
Aug 19, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Single arm pilot study to evaluate the safety and initial feasibility of the Neurolyser XR, a high intensity focused ultrasound device, for non-invasive treatment of axial chronic low back pain

Conditions

  • Facet Syndrome of Lumbar Spine

Interventions

  • Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XRDevice

    Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numerical rating scale of pain (NRS)Time frame: Time Frame: Base line, 2 days 1, 2 & 4 weeks, 3, 6 & 12 months after procedure
  2. SafteyTime frame: Time Frame: 6 months after procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rambam

    Haifa, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.